Morton Scheinberg
6 Papers
70 Citations
Morton Scheinberg is an academic researcher. The author has contributed to research in topics: Biosimilar & Health care. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
The advent of biosimilar therapies in rheumatology—“O Brave New World”
Morton Scheinberg,Jonathan Kay +1 more
TL;DR: The development of biosimilar therapies for the treatment of patients with rheumatic diseases could potentially result in substantial cost savings for patients and health care providers, and consequently, increased availability of effective therapies.
109
Biosimilars in rheumatology: what the clinician should know
TL;DR: Clinical evidence on biosimilars that have been approved recently or are presently being developed for use in rheumatology is reviewed and contrasted with that available for biomimics (or intended copies), which are non-innovator biologics that are marketed in several countries but have not undergone review according to a regulatory pathway.
43
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
TL;DR: Comments on various aspects surrounding the use of such biocopies in clinical rheumatology are commented on.
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial
Josef S Smolen,Stanley Cohen,Hans-Peter Tony,Morton Scheinberg,Alan Kivitz,Andra Balanescu,Juan J. Gomez-Reino,Liyi Cen,Johann Poetzl,Tamas Shisha,Dmitrij Kollins +10 more
TL;DR: SDZ-RTX demonstrated similar B cell concentrations over time, efficacy, safety and immunogenicity to Ref- RTX over 52 weeks of the ASSIST-RA study.
19
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
Morton Scheinberg,Carlos Pineda,Gilberto Castañeda-Hernández,Juan José Zarbá,Aderson Omar Mourão Cintra Damião,Luiz H. Arantes,Ira Jacobs +6 more
TL;DR: The situation in Latin American countries is complicated by the presence of “non-comparable biotherapeutics” (also known as “intended copies”), which have not been rigorously compared with the originator product.
10